JP2019523214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523214A5 JP2019523214A5 JP2018557405A JP2018557405A JP2019523214A5 JP 2019523214 A5 JP2019523214 A5 JP 2019523214A5 JP 2018557405 A JP2018557405 A JP 2018557405A JP 2018557405 A JP2018557405 A JP 2018557405A JP 2019523214 A5 JP2019523214 A5 JP 2019523214A5
- Authority
- JP
- Japan
- Prior art keywords
- ala
- drug conjugate
- iii
- edfyd
- bt17bdc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N Mesitylene Chemical group CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 1
Claims (4)
- ＢＴ１７ＢＤＣ−２７
- スキームＩにおいて記載されている合成経路を含む、請求項１に記載の薬物コンジュゲートを調製する方法。
- １種もしくは複数の薬学的に許容される添加剤と組み合わせて、請求項１に記載の薬物コンジュゲートを含む医薬組成物。
- がん、特に、固形腫瘍、例えば、非小細胞肺がんの予防、抑制または処置において使用するための、請求項１に記載の薬物コンジュゲート。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1607827.1 | 2016-05-04 | ||
| GBGB1607827.1A GB201607827D0 (en) | 2016-05-04 | 2016-05-04 | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| PCT/GB2017/051250 WO2017191460A1 (en) | 2016-05-04 | 2017-05-04 | Bicyclic peptide-toxin conjugates specific for mt1-mmp |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523214A JP2019523214A (ja) | 2019-08-22 |
| JP2019523214A5 true JP2019523214A5 (ja) | 2020-06-18 |
| JP6942147B2 JP6942147B2 (ja) | 2021-09-29 |
Family
ID=56234400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557405A Active JP6942147B2 (ja) | 2016-05-04 | 2017-05-04 | Ｍｔ１−ｍｍｐに対して特異的な二環式ペプチド−毒素コンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10994019B2 (ja) |
| EP (1) | EP3452096A1 (ja) |
| JP (1) | JP6942147B2 (ja) |
| CN (1) | CN109414510B (ja) |
| GB (1) | GB201607827D0 (ja) |
| WO (1) | WO2017191460A1 (ja) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3215518T3 (pl) | 2014-10-29 | 2021-08-23 | Bicyclerd Limited | Bicykliczne ligandy peptydowe swoiste wobec MT1-MMP |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018096365A1 (en) * | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| EP3565638B8 (en) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Bicycle conjugate for treating cancer |
| WO2018163131A1 (en) | 2017-03-10 | 2018-09-13 | Quiapeg Pharmaceuticals Ab | Releasable conjugates |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| WO2019025811A1 (en) | 2017-08-04 | 2019-02-07 | Bicycletx Limited | SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137 |
| EP3668550A1 (en) * | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| EP3755725A1 (en) * | 2018-02-23 | 2020-12-30 | BicycleTX Limited | Multimeric bicyclic peptide ligands |
| AU2019232652B2 (en) | 2018-03-09 | 2022-04-21 | Quiapeg Pharmaceuticals Ab | Releasable antibody conjugates |
| GB201810329D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to integrin avB3 |
| GB201810320D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
| GB201810327D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| JP2021535920A (ja) | 2018-09-12 | 2021-12-23 | キアペグ ファーマシューティカルズ アクチエボラグ | 放出可能なｇｌｐ−１コンジュゲート |
| JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
| GB201820295D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| CA3122669A1 (en) * | 2018-12-13 | 2020-06-18 | Bicycletx Limited | Bicyclic peptide ligands specific for mt1-mmp |
| JP2022514618A (ja) * | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| JP2022514687A (ja) * | 2018-12-21 | 2022-02-14 | バイスクルアールディー・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| GB201900526D0 (en) * | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for caix |
| JP2022532134A (ja) * | 2019-05-09 | 2022-07-13 | バイスクルテクス・リミテッド | Ｏｘ４０に特異的な二環式ペプチドリガンド |
| TW202108165A (zh) | 2019-05-10 | 2021-03-01 | 英商拜西克爾德有限公司 | 治療癌症之方法 |
| CN112048013B (zh) * | 2019-06-05 | 2021-11-05 | 深圳先进技术研究院 | 靶向脑胶质瘤的多肽化合物及其合成方法与应用 |
| TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN114867753A (zh) * | 2019-10-03 | 2022-08-05 | 拜斯科技术开发有限公司 | 异串联双环肽复合物 |
| MX2023001466A (es) | 2020-08-03 | 2023-03-03 | Bicycletx Ltd | Enlazadores de base peptidica. |
| AU2022206395A1 (en) | 2021-01-11 | 2023-08-17 | Bicycletx Limited | Methods for treating cancer |
| MX2023007788A (es) | 2021-01-24 | 2023-11-17 | Michael David Forrest | Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos. |
| GB202114282D0 (en) | 2021-10-06 | 2021-11-17 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
| EP4417618A1 (en) * | 2021-10-14 | 2024-08-21 | Xizang Haisco Pharmaceutical Co., Ltd. | Epha2 bicyclic peptide ligand and conjugate thereof |
| CN118251405A (zh) * | 2021-11-16 | 2024-06-25 | 西藏海思科制药有限公司 | Mt1-mmp的双环肽配体及其缀合物 |
| GB202214528D0 (en) | 2022-10-03 | 2022-11-16 | Owlstone Med Ltd | A compound |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006500364A (ja) * | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| EP1618897A4 (en) * | 2003-04-04 | 2010-09-29 | Eisai R&D Man Co Ltd | LIPID MEMBRANE STRUCTURE COMPRISING AN ANTI-MT-MMP MONOCLONAL ANTIBODY |
| CA2595902C (en) | 2005-01-24 | 2017-08-22 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors |
| DK2257624T5 (da) | 2008-02-05 | 2012-09-10 | Medical Res Council | Fremgangsmåder og sammensætninger |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| JP2013518558A (ja) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 構造化されたペプチドプロセシング |
| DK2764140T3 (en) * | 2011-10-07 | 2017-12-04 | Bicyclerd Ltd | MODULATION OF STRUCTURED POLYPEPTIME SPECIFICITY |
| US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| SG11201602889TA (en) | 2013-10-28 | 2016-05-30 | Bicycle Therapeutics Ltd | Novel polypeptides |
| PL3215518T3 (pl) | 2014-10-29 | 2021-08-23 | Bicyclerd Limited | Bicykliczne ligandy peptydowe swoiste wobec MT1-MMP |
| GB201600911D0 (en) * | 2016-01-18 | 2016-03-02 | Bicycle Therapeutics Ltd | Stabilized peptide derivatives |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018096365A1 (en) | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| BR112019012623A2 (pt) | 2016-12-23 | 2019-11-19 | Bicycletx Ltd | ligantes peptídicos para ligação a mt1-mmp |
| EP3565638B8 (en) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Bicycle conjugate for treating cancer |
| GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| EP3755725A1 (en) | 2018-02-23 | 2020-12-30 | BicycleTX Limited | Multimeric bicyclic peptide ligands |
| WO2019193328A1 (en) | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
| CA3116504A1 (en) | 2018-10-30 | 2020-05-07 | Bicyclerd Limited | Bt1718 for use in treating cancer |
-
2016
- 2016-05-04 GB GBGB1607827.1A patent/GB201607827D0/en not_active Ceased
-
2017
- 2017-05-04 WO PCT/GB2017/051250 patent/WO2017191460A1/en unknown
- 2017-05-04 EP EP17723745.0A patent/EP3452096A1/en active Pending
- 2017-05-04 CN CN201780031804.XA patent/CN109414510B/zh active Active
- 2017-05-04 JP JP2018557405A patent/JP6942147B2/ja active Active
- 2017-05-04 US US16/097,305 patent/US10994019B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523214A5 (ja) | ||
| JP2018024682A5 (ja) | ||
| MA46709A (fr) | Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale | |
| JP2013166763A5 (ja) | ||
| JP2017537066A5 (ja) | ||
| MA33590B1 (fr) | Utilisation d'activateurs du récepteur nicotinique de l'acétylcholine alpha7 | |
| IL292193B1 (en) | Anti-B7-H1 antibodies for the treatment of tumors | |
| JP2009505676A5 (ja) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2010501534A5 (ja) | ||
| JP2009545527A5 (ja) | ||
| CL2009000200A1 (es) | Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune. | |
| JP2014519662A5 (ja) | ||
| CY1108885T1 (el) | Συνδυασμοι περιλαμβανοντες αντιμουσκαρινους παραγοντες και κορτικοστεροειδη | |
| JP2018531941A5 (ja) | ||
| WO2017176744A8 (en) | Methods of treating pediatric cancers | |
| JP2019515908A5 (ja) | ||
| JP2016525097A5 (ja) | ||
| EP3932907A3 (en) | Dextromethorphan analogs and combinations of deuterated dextromethorphan and nortriptyline for use in treating agitation and/or aggression | |
| EA201000039A1 (ru) | Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль | |
| JP2014534269A5 (ja) | ||
| JP2015502926A5 (ja) | ||
| WO2017106175A3 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION | |
| EA201991877A2 (ru) | 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения | |
| CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. |